BeOne Medicines Ltd. (ONC) stock
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 14/301935% above fair value
$416.54+0.58 (+0.14%)
Close on Nov 13, 2026Market cap $47.36BP/E 53.4Yield –
BeOne Medicines total assets
Total assets on the balance sheet at the end of each period.
BeOne Medicines's total assets was $9.88B at Sep 30, 2026. For fiscal 2025 it was $8.19B, up 38.3% from the year before. Over ten years it grew 53.0% a year on average. The highest annual figure on record is $8.54B in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.19B | +38.3% |
| FY2024 | Dec 31, 2024 | $5.92B | +2.0% |
| FY2023 | Dec 31, 2023 | $5.81B | -9.0% |
| FY2022 | Dec 31, 2022 | $6.38B | -25.3% |
| FY2021 | Dec 31, 2021 | $8.54B | +52.4% |
| FY2020 | Dec 31, 2020 | $5.60B | +247.4% |
| FY2019 | Dec 31, 2019 | $1.61B | -28.3% |
| FY2018 | Dec 31, 2018 | $2.25B | +115.0% |
| FY2017 | Dec 31, 2017 | $1.05B | +157.9% |
| FY2016 | Dec 31, 2016 | $405.81M | +247.5% |
| FY2015 | Dec 31, 2015 | $116.76M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $9.88B | +29.4% |
| Q2 FY2026 | Jun 30, 2026 | $9.18B | +45.7% |
| Q1 FY2026 | Mar 31, 2026 | $8.55B | +46.4% |
| Q4 FY2025 | Dec 31, 2025 | $8.19B | +38.3% |
| Q3 FY2025 | Sep 30, 2025 | $7.63B | +30.9% |
| Q2 FY2025 | Jun 30, 2025 | $6.30B | +10.3% |
| Q1 FY2025 | Mar 31, 2025 | $5.84B | +3.1% |
| Q4 FY2024 | Dec 31, 2024 | $5.92B | +2.0% |
| Q3 FY2024 | Sep 30, 2024 | $5.83B | +5.5% |
| Q2 FY2024 | Jun 30, 2024 | $5.71B | -0.3% |
| Q1 FY2024 | Mar 31, 2024 | $5.67B | -4.9% |
| Q4 FY2023 | Dec 31, 2023 | $5.81B | -9.0% |
| Q3 FY2023 | Sep 30, 2023 | $5.52B | -17.9% |
| Q2 FY2023 | Jun 30, 2023 | $5.73B | -22.4% |
| Q1 FY2023 | Mar 31, 2023 | $5.96B | -25.7% |
| Q4 FY2022 | Dec 31, 2022 | $6.38B | -25.3% |
| Q3 FY2022 | Sep 30, 2022 | $6.73B | +27.2% |
| Q2 FY2022 | Jun 30, 2022 | $7.38B | +33.6% |
| Q1 FY2022 | Mar 31, 2022 | $8.02B | +37.8% |
| Q4 FY2021 | Dec 31, 2021 | $8.54B | +52.4% |
| Q3 FY2021 | Sep 30, 2021 | $5.29B | -5.0% |
| Q2 FY2021 | Jun 30, 2021 | $5.52B | +41.5% |
| Q1 FY2021 | Mar 31, 2021 | $5.82B | +43.1% |
| Q4 FY2020 | Dec 31, 2020 | $5.60B | +247.4% |
| Q3 FY2020 | Sep 30, 2020 | $5.57B | +195.9% |
| Q2 FY2020 | Jun 30, 2020 | $3.90B | +81.5% |
| Q1 FY2020 | Mar 31, 2020 | $4.07B | +87.2% |
| Q4 FY2019 | Dec 31, 2019 | $1.61B | -28.3% |
| Q3 FY2019 | Sep 30, 2019 | $1.88B | -21.9% |
| Q2 FY2019 | Jun 30, 2019 | $2.15B | +30.0% |
| Q1 FY2019 | Mar 31, 2019 | $2.17B | +27.1% |
| Q4 FY2018 | Dec 31, 2018 | $2.25B | +115.0% |
| Q3 FY2018 | Sep 30, 2018 | $2.41B | +129.6% |
| Q2 FY2018 | Jun 30, 2018 | $1.65B | +248.9% |
| Q1 FY2018 | Mar 31, 2018 | $1.71B | +353.6% |
| Q4 FY2017 | Dec 31, 2017 | $1.05B | +157.9% |
| Q3 FY2017 | Sep 30, 2017 | $1.05B | – |
| Q2 FY2017 | Jun 30, 2017 | $473.98M | – |
| Q1 FY2017 | Mar 31, 2017 | $376.73M | – |
| Q4 FY2016 | Dec 31, 2016 | $405.81M | – |
See a number that looks wrong?